Tapotoclax by Amgen for Myelodysplastic Syndrome: Likelihood of Approval
Tapotoclax is under clinical development by Amgen and currently in Phase I for Myelodysplastic Syndrome.
Tapotoclax is under clinical development by Amgen and currently in Phase I for Myelodysplastic Syndrome.
What's Your Reaction?
